📊 JBIO Key Takeaways
Is Jade Biosciences, Inc. (JBIO) a Good Investment?
Jade Biosciences is a pre-revenue pharmaceutical company with no commercialized products and accelerating operating losses of -$43.4M. With negative free cash flow of -$24.3M annually and only $55.1M in cash, the company faces approximately 2-3 years of runway before requiring additional funding or revenue generation, creating substantial execution risk.
Jade Biosciences appears to be a pre-revenue biotech with strong liquidity and no debt, but fundamentals show deep operating and net losses with worsening YoY profitability. With ~$88M in cash against roughly ~$95M annual operating cash outflow, runway is limited and external financing is likely. Until cash burn moderates and there is tangible progress toward revenue or non-dilutive funding, the risk profile remains unfavorable.
Jade Biosciences, Inc. Key Strengths (JBIO)
- Strong balance sheet with $296.5M stockholders' equity
- Excellent liquidity position with 14.29x current and quick ratios
- Minimal debt burden with 0.00x debt-to-equity ratio and low liabilities at $23.0M
- Exceptional liquidity (21.09x current/quick ratio)
- Debt-free balance sheet with minimal interest burden
- Large equity base relative to modest liabilities
JBIO Stock Risks: Jade Biosciences, Inc. Investment Risks
- Complete absence of revenue indicates no commercialized products or market traction
- Operating losses accelerating with net income deteriorating -27.2% YoY and EPS declining -30.7% YoY
- Negative free cash flow of -$24.3M annually creating limited runway with current cash reserves
- High execution risk typical of pharmaceutical development stage companies dependent on FDA approval and clinical trial success
- Pre-revenue status with substantial operating losses
- Limited cash runway given current burn rate
- High dilution/financing risk to sustain operations
Key Metrics to Watch
- Revenue generation and commercialization milestones
- Cash burn rate and months of cash runway remaining
- Clinical trial progress and regulatory approval status
- Quarterly operating cash burn (OCF)
- Cash & equivalents (runway months)
Jade Biosciences, Inc. (JBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.29x current ratio provides a solid financial cushion.
JBIO Profit Margin, ROE & Profitability Analysis
JBIO vs Healthcare Sector: How Jade Biosciences, Inc. Compares
How Jade Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Jade Biosciences, Inc. Stock Overvalued? JBIO Valuation Analysis 2026
Based on fundamental analysis, Jade Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Jade Biosciences, Inc. Balance Sheet: JBIO Debt, Cash & Liquidity
JBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Jade Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-14.89 indicates the company is currently unprofitable.
JBIO Revenue Growth, EPS Growth & YoY Performance
Jade Biosciences, Inc. Dividends, Buybacks & Capital Allocation
JBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Jade Biosciences, Inc. (CIK: 0001798749)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JBIO
What is the AI rating for JBIO?
Jade Biosciences, Inc. (JBIO) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are JBIO's key strengths?
Claude: Strong balance sheet with $296.5M stockholders' equity. Excellent liquidity position with 14.29x current and quick ratios. ChatGPT: Exceptional liquidity (21.09x current/quick ratio). Debt-free balance sheet with minimal interest burden.
What are the risks of investing in JBIO?
Claude: Complete absence of revenue indicates no commercialized products or market traction. Operating losses accelerating with net income deteriorating -27.2% YoY and EPS declining -30.7% YoY. ChatGPT: Pre-revenue status with substantial operating losses. Limited cash runway given current burn rate.
What is JBIO's revenue and growth?
Jade Biosciences, Inc. reported revenue of N/A.
Does JBIO pay dividends?
Jade Biosciences, Inc. does not currently pay dividends.
Where can I find JBIO SEC filings?
Official SEC filings for Jade Biosciences, Inc. (CIK: 0001798749) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JBIO's EPS?
Jade Biosciences, Inc. has a diluted EPS of $-0.57.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is JBIO's fundamental grade?
Based on our AI fundamental analysis in May 2026, Jade Biosciences, Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is JBIO stock overvalued or undervalued?
Valuation metrics for JBIO: ROE of -13.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is JBIO's AI grade for 2026?
Our dual AI analysis gives Jade Biosciences, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is JBIO's free cash flow?
Jade Biosciences, Inc.'s operating cash flow is $-24.1M, with capital expenditures of $196.0K.
How does JBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -13.6% (avg: 15%), current ratio 14.29 (avg: 2).